IPOdesktop • Wed, Jun. 18
- A development stage emerging therapeutic and diagnostic company focusing on microRNA and its role in oncology.
- Entered into agreements with an affiliate of the Ohio State University (OSU), to exclusively license a portfolio of approximately 100 pending patent applications.
- Has not yet initiated any clinical trials or validated its candidate diagnostic tests.
There are no Transcripts on MCLB.
We currently have no Breaking News on this stock.
MCLB vs. ETF Alternatives
Currently, there's no company description for MCLB.
Country: United States
Other News & PR